文献速递冠心病血脂与心血管预防

阿利西尤单抗减少急性冠脉综合征后总非致死性心血管事件与死亡:ODYSSEY OUTCOMES 试验

Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial.
PubMed 文献 · J Am Coll Cardiol · 2018-11-11

ODYSSEY OUTCOMES 试验比较阿利西尤单抗与安慰剂(均加高强度或最大耐受他汀)用于 18,924 例急性冠脉综合征(ACS)患者。本预设分析采用共享脆弱模型联合估计总非致死性心血管事件与死亡,显示阿利西尤单抗减少总非致死性心血管事件(HR 0.87,95%CI 0.82–0.93)和死亡(HR 0.83,95%CI 0.71–0.97)。

要点

  • 阿利西尤单抗减少总非致死性心血管事件,HR 0.87(95%CI 0.82–0.93)。
  • 阿利西尤单抗减少死亡,HR 0.83(95%CI 0.71–0.97)。
  • 预防的总事件数为首次事件数的两倍,总事件减少更全面反映疗效。

核心结论

  • 在 ACS 患者中,阿利西尤单抗预防的总非致死性心血管事件和死亡数是首次事件数的两倍。
  • 总事件减少是更全面捕捉阿利西尤单抗 ACS 后临床疗效的指标。

研究设计与样本

  • ODYSSEY OUTCOMES 试验的预设分析,比较阿利西尤单抗与安慰剂(均加高强度或最大耐受他汀)用于 18,924 例 ACS 患者。
  • 采用共享脆弱模型联合估计总非致死性心血管事件与死亡,关联参数量化非致死事件与死亡风险的关联强度。

主要发现

  • 共 3,064 次首次事件和 5,425 次总事件,阿利西尤单抗组较安慰剂组少 190 次首次和 385 次总非致死性心血管事件或死亡。
  • 阿利西尤单抗减少总非致死性心血管事件(HR 0.87;95%CI 0.82–0.93)。
  • 阿利西尤单抗减少死亡(HR 0.83;95%CI 0.71–0.97),且非致死事件与致死事件风险存在强关联。

临床怎么用

  • 在 ACS 后患者中,评估阿利西尤单抗疗效时可关注总事件(包括复发事件)的减少,而非仅首次事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial compared alirocumab with placebo, added to high-intensity or maximum-tolerated statin treatment, after acute coronary syndrome (ACS) in 18,924 patients. Alirocumab reduced the first occurrence of the primary composite endpoint and was associated with fewer all-cause deaths. OBJECTIVES: This pre-specified analysis determined the extent to which alirocumab reduced total (first and subsequent) nonfatal cardiovascular events and all-cause deaths in ODYSSEY OUTCOMES. METHODS: Hazard functions for total nonfatal cardiovascular events (myocardial infarction, stroke, ischemia-driven coronary revascularization, and hospitalization for unstable angina or heart failure) and death were jointly estimated, linked by a shared frailty accounting for patient risk heterogeneity and correlated within-patient nonfatal events. An association parameter also quantified the strength of the linkage between risk of nonfatal events and death. The model provides accurate relative estimates of nonfatal event risk if nonfatal events are associated with increased risk for death. RESULTS: With 3,064 first and 5,425 total events, 190 fewer first and 385 fewer total nonfatal cardiovascular events or deaths were observed with alirocumab compared with placebo. Alirocumab reduced total nonfatal cardiovascular events (hazard ratio: 0.87; 95% confidence interval: 0.82 to 0.93) and death (hazard ratio: 0.83; 95% confidence interval: 0.71 to 0.97) in the presence of a strong association between nonfatal and fatal event risk. CONCLUSIONS: In patients with ACS, the total number of nonfatal cardiovascular events and deaths prevented with alirocumab was twice the number of first events prevented. Consequently, total event reduction is a more comprehensive metric to capture the totality of alirocumab clinical efficacy after ACS.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Szarek M, White HD, Schwartz GG, et al. Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial. J Am Coll Cardiol. 2018. PMID: 30428396. doi:10.1016/j.jacc.2018.10.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。